S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/BVF Partners/Q2 2021

BVF Partners

Period: Q2 2021 Β· Filed: 2021-08-16
View on SEC EDGAR β†—
AUM
$2.67B
Total portfolio value
Positions
70
Reported securities
Top Holding
GHRS
7.5% $201.6M
QoQ Changes
+8 / -6
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2021-08-16) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
GHRSGH RESEARCH PLC$201.6M7.55%$21.73$27.01+24.3%
7.5%
ARGXARGENX SE$196.1M7.35%$301.07$939.68+212.1%
7.3%
OLMAOLEMA PHARMACEUTICALS INC$186.4M6.99%$27.98$12.64-54.8%
7.0%
PTGXPROTAGONIST THERAPEUTICS INC$168.5M6.31%$44.88$131.62+193.3%
6.3%
MRUSMERUS N V$153.5M5.75%β€”β€”
5.8%
KYMRKYMERA THERAPEUTICS INC$127.6M4.78%$48.50$113.51+134.0%
4.8%
XOMAXOMA CORP DEL$120.0M4.50%$34.00$43.00+26.5%
4.5%
RPTXREPARE THERAPEUTICS INC$116.1M4.35%β€”β€”
4.3%
RLAYRELAY THERAPEUTICS INC$107.5M4.03%$36.59$18.65-49.0%
4.0%
RVMDREVOLUTION MEDICINES INC$78.9M2.96%$31.74$189.24+496.2%
3.0%
RCUSARCUS BIOSCIENCES INC$76.8M2.88%$27.46$30.33+10.4%
2.9%
EPIXESSA PHARMA INC$70.0M2.63%β€”β€”
2.6%
ACIUAC IMMUNE SA$67.8M2.54%$7.93$2.51-68.3%
2.5%
FDMT4D MOLECULAR THERAPEUTICS IN$48.3M1.81%$24.08$13.00-46.0%
1.8%
VSTMXXXXVERASTEM INC$45.9M1.72%β€”β€”
1.7%
SNDXSYNDAX PHARMACEUTICALS INC$42.7M1.60%$17.17$21.82+27.1%
1.6%
LXRXLEXICON PHARMACEUTICALS INC$38.5M1.44%$4.59$2.32-49.5%
1.4%
REPLREPLIMUNE GROUP INC$35.3M1.32%$38.42$11.58-69.9%
1.3%
VIRXVIRACTA THERAPEUTICS INC$35.1M1.32%β€”β€”
1.3%
KURAKURA ONCOLOGY INC$34.1M1.28%$20.85$11.10-46.8%
1.3%
RAINRAIN THERAPEUTICS INC$30.2M1.13%β€”$1.97
1.1%
SPROSPERO THERAPEUTICS INC$29.9M1.12%$13.96$2.20-84.2%
1.1%
JANXJANUX THERAPEUTICS INC$29.4M1.10%$24.95$15.54-37.7%
1.1%
XENEXENON PHARMACEUTICALS INC$29.3M1.10%$18.62$60.96+227.4%
1.1%
RACATHERAPEUTICS ACQUISITION COR$28.5M1.07%β€”β€”
1.1%
OVIDOVID THERAPEUTICS INC$25.9M0.97%$3.91$2.69-31.2%
1.0%
INFIQINFINITY PHARMACEUTICALS INC$25.1M0.94%$2.99$0.00
0.9%
IKNAIKENA ONCOLOGY INC$24.8M0.93%β€”β€”
0.9%
MTEMXXXXMOLECULAR TEMPLATES INC$22.3M0.84%β€”β€”
0.8%
CTICCTI BIOPHARMA CORP$22.3M0.84%β€”β€”
0.8%

Quarter-on-Quarter Activity

Q2 2021 vs. Q1 2021

New Positions (8)

TickerIssuerNotionalSince Filing
GHRSGH RESEARCH PLC$201.6M+24.3%
RAINRAIN THERAPEUTICS INC$30.2M
JANXJANUX THERAPEUTICS INC$29.4M-37.7%
ELEVELEVATION ONCOLOGY INC$21.6M
DAWNDAY ONE BIOPHARMACEUTICALS I$20.9M
NGMNGM BIOPHARMACEUTICALS INC$18.8M
ACRSACLARIS THERAPEUTICS INC$17.6M
CNTACENTESSA PHARMACEUTICALS PLC$1.3M

Exited Positions (6)

TickerIssuerNotional
FPRXFIVE PRIME THERAPEUTICS INC$238.8M
IONSIONIS PHARMACEUTICALS INC$61.4M
IDYAIDEAYA BIOSCIENCES INC$61.3M
CTMXCYTOMX THERAPEUTICS INC$43.1M
BCTGBCTG ACQUISITION CORP$8.9M
LSAQLIFESCI ACQUISITION II CORP$1.0M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
SNDXSYNDAX PHARMACEUTICALS INC$39.0M+1420.5%+27.1%
RACATHERAPEUTICS ACQUISITION COR$20.4M+259.0%
ARGXARGENX SE$110.8M+110.3%+212.1%
PHXMERYTECH PHARMA$1.9M+110.3%
REPLREPLIMUNE GROUP INC$21.2M+99.1%-69.9%
FDMT4D MOLECULAR THERAPEUTICS IN$3.6M+94.5%-46.0%
RCUSARCUS BIOSCIENCES INC$24.1M+49.1%+10.4%
CALACALITHERA BIOSCIENCES INC$1.8M+31.1%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
XENEXENON PHARMACEUTICALS INC$-33.1M-54.9%+227.4%
ANABANAPTYSBIO INC$-4.7M-32.0%
CGEMCULLINAN ONCOLOGY INC$-24.8M-29.9%
RNACSELECTA BIOSCIENCES INC$-3.7M-28.8%
VRDNVIRIDIAN THERAPEUTICS INC$-1.3M-24.5%
XFORXXXXX4 PHARMACEUTICALS INC$-3.9M-22.3%
FWPAYFORWARD PHARMA A/S$0.1M-18.4%
FBRXFORTE BIOSCIENCES INC$-4.7M-17.7%
← Back to Hedge Funds